Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829534 | 0.83 | POLB (0.51) | MEN1KMT2A | |
| SCHEMBL4886749 | 0.82 | MAPK14 (0.52) | MAPK14MCL1 | |
| SCHEMBL1140575 | 0.79 | MAPK14 (0.52) | MAPK14MCL1 | |
| SCHEMBL4827748 | 0.78 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL4827243 | 0.75 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL3656842 | 0.72 | MEN1 (0.68) | HCAR1MEN1KMT2AMCL1ATM | |
| SCHEMBL4887021 | 0.71 | SCD (0.62) | MAPK14 | |
| SCHEMBL4879776 | 0.71 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL16204799 | 0.70 | MEN1 (0.55) | HCAR1MEN1KMT2AMCL1 | |
| SCHEMBL3751890 | 0.70 | CHEK1 (0.51) | MEN1KMT2AMCL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| CN-101001845-A | Substituted quinazolones as anti-cancer agents. | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | HCAR1 4034/4885MAPK14 153/4885MEN1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.